NCT06314607 Genetic and Molecular Characterization of Nervous System Lesions
| NCT ID | NCT06314607 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Condition | Brain Tumor |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2024-03-26 |
| Primary Completion | 2034-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 2024-03-26 with a primary completion date of 2034-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Primary and secondary brain tumors, the leading cause of death from cancer before the age of 35, represent a complex and heterogeneous group of pathologies with a generally poor prognosis. Knowledge of these tumors has made enormous strides thanks to access to biological samples, leading to a much more robust, reliable and precise histo-pronostic classification, but also, increasingly, to the identification of theranostic targets. Despite these advances, there is a real need to refine diagnostic and prognostic classification, identify the biological mechanisms involved in the formation and progression of these pathologies, develop new targeted strategies, and devise minimally invasive follow-up methods (liquid biopsies). In addition, certain non-tumoral brain lesions (e.g. malformations) can be similarly classified according to their molecular and mutational profile. This project aims to make a decisive contribution to these objectives.
Eligibility Criteria
Inclusion Criteria: * Any patient operated on for a brain lesion (e.g. tumors: glioma, LCPSNC, meningioma, or rare tumor) and/or followed up for one of these pathologies. * Age ≥ 18 years * Consent or non-opposition of the patient or his/her legal representative (guardian) to participate in the study. Exclusion Criteria: NA
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06314607 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Brain Tumor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06314607 currently recruiting?
Yes, NCT06314607 is actively recruiting participants. Contact the research team at marc.sanson@aphp.fr for enrollment information.
Where is the NCT06314607 trial being conducted?
This trial is being conducted at Paris, France, Paris, France, Paris, France.
Who is sponsoring the NCT06314607 clinical trial?
NCT06314607 is sponsored by Assistance Publique - Hôpitaux de Paris. The trial plans to enroll 10,000 participants.